Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Summary

This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a single agent or with chemotherapy.

Timeline

Start

2017-11-09

Primary completion

2019-07-22

Completion

2019-07-22

Drugs

Indications